109 Lebrikizumab Allows Interleukin-13 Membrane Binding and Subsequent Internalization through the Decoy Receptor Interleukin-13 Receptor Alpha 2

Abstract

Lebrikizumab (lebri) is a novel, monoclonal antibody that selectively targets interleukin (IL)-13 and prevents formation of the IL-13 receptor alpha 1 (Rα1)/IL-4 receptor alpha (Rα) heterodimer receptor signaling complex. A previous crystal structure report showed that lebri does not interfere with binding of IL-13 to the IL-13 Receptor alpha 2 (Ra2) decoy receptor. In contrast, other IL-13 antibodies tralokinumab and cendakimab had been reported to inhibit IL-13 binding to both IL-13Ra1 and IL-13Ra2.